CRO Mosaic Biosciences has partnered with clinical stage drug development company Uniquity Bio to advance candidate selection in clinical programmes.
Mosaic specialises in platform-agnostic approaches to drug development, biologics discovery and lead optimisation. “We built Mosaic around the belief that the best discovery strategy is one tailored to the biology, not the platform,” said Mosaic Biosciences CEO Jean-Pierre Wery.
“Uniquity Bio shares that science-first philosophy, and we’re proud to support their mission to bring meaningful new medicines to patients.”
By combining Mosaic’s discovery model with Uniquity Bio’s scientific and operational experience, the two organisations aim to advance high-quality biologic candidates with the speed and precision clinical stage programmes require.
“Mosaic brings a level of scientific depth and strategic partnership in support of clinical stage and discovery programs that goes beyond traditional CRO relationships,” said Kiyomi Komori, VP, Translational Medicine of Uniquity “Their integrated approach and broad discovery capabilities align well with how we think about advancing our pipeline.”
